Does omalizumab really benefit patients with severe asthma?, asks DTB

Omalizumab is an injectable treatment for people with severe, allergic asthma that is not controlled by standard therapies. But a lack of evidence to support use of the drug in this group of patients does not justify its high cost, says Drug and Therapeutics Bulletin (DTB) in its review this month.

Dr Ike Iheanacho, editor of DTB comments: “The annual cost of omalizumab ranges from around £3,000 to £20,000 excluding the cost of a healthcare professional preparing and giving the injections.

However, in the key published study that has assessed its effectiveness in patients with severe asthma, omalizumab provided, at best, only a marginal reduction in the rate of asthma exacerbations. There is simply not enough evidence to justify omalizumab’s hype as a wonder drug.”

DTB believes that omalizumab should only be used in the context of clinical trials that aim to provide information on its efficacy in preventing exacerbations, hospital admissions and oral corticosteroid use, as well as its cost-effectiveness.

Also in DTB this month:

When and how it is best to give combination therapy for early rheumatoid arthritis?

  • Around one per cent of adults in the UK have rheumatoid arthritis.
  • Early intervention can reduce long-term joint damage so, patients need to be seen early (preferably within 3 months of first being seen) by a rheumatologist for initiation of disease-modifying-anti-rheumatic drugs (DMARDs).
  • DTB looks at the use of DMARDs to assess whether they should be administered as sole therapy or in combination.  It also looks at when and how best to give combination therapy.

Contact Vicky Taylor on 0207 770 7567 / vicky.taylor@which.co.uk

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register

Already registered?

Sign in

Follow Us:

Just published

Under 40s to be offered alternative to AstraZeneca COVID-19 vaccine

Under 40s to be offered alternative to AstraZeneca COVID-19 vaccine

Patients aged 30-39 will be offered an alternative to the Oxford/AstraZeneca COVID-19...

GPs per patient down 10% in just five years, NHS data reveal

GPs per patient down 10% in just five years, NHS data reveal

The number of fully-qualified, full-time equivalent (FTE) GPs per patient in England...

Supportive model must replace harmful CQC inspections, BMA chair warns

Supportive model must replace harmful CQC inspections, BMA chair warns

CQC inspections that ‘divert time away from patient care’ and ‘instil fear’ among...

UK COVID-19 vaccination programme tracker

UK COVID-19 vaccination programme tracker

GPs across the UK are playing a leading role in the largest-ever NHS vaccination...

A 'tsunami' of work is drowning general practice: GPs speak out about a profession at its limit

A 'tsunami' of work is drowning general practice: GPs speak out about a profession at its limit

Rocketing workloads created by huge backlogs of cases and continuing COVID-19 disruption...

Slight increase in GP workforce during past year, but number of partners continues to fall

Slight increase in GP workforce during past year, but number of partners continues to fall

The GP workforce grew by 0.4% in the year to March 2021, but the number of GP partners...